Merck & Co., Inc.
Merck & Co., Inc. Fundamental Analysis
Merck & Co., Inc. (MRK) shows weak financial fundamentals with a PE ratio of 30.81, profit margin of 13.62%, and ROE of 17.93%. The company generates $65.5B in annual revenue with weak year-over-year growth of 1.31%.
Key Strengths
Areas of Concern
The stock receives a Fundamental Health Score of 53.8/100 based on profitability, valuation, growth, and balance sheet metrics. The C grade reflects average fundamentals, with notable risks in certain areas.
Fundamental Health Score
We analyze MRK's fundamental strength across five key dimensions:
Efficiency Score
WeakMRK struggles to generate sufficient returns from assets.
Valuation Score
ModerateMRK shows balanced valuation metrics.
Growth Score
WeakMRK faces weak or negative growth trends.
Financial Health Score
ModerateMRK shows balanced financial health with some risks.
Profitability Score
ModerateMRK maintains healthy but balanced margins.
Key Financial Metrics
Is MRK Expensive or Cheap?
P/E Ratio
MRK trades at 30.81 times earnings. This suggests a premium valuation.
PEG Ratio
When adjusting for growth, MRK's PEG of -0.64 indicates potential undervaluation.
Price to Book
The market values Merck & Co., Inc. at 6.00 times its book value. This suggests the stock is fully valued or overvalued on an asset basis.
EV/EBITDA
Enterprise value stands at 10.19 times EBITDA. This signals the market has high growth expectations.
How Well Does MRK Make Money?
Net Profit Margin
For every $100 in sales, Merck & Co., Inc. keeps $13.62 as profit after all expenses.
Operating Margin
Core operations generate 27.59 in profit for every $100 in revenue, before interest and taxes.
ROE
Management delivers $17.93 in profit for every $100 of shareholder equity.
ROA
Merck & Co., Inc. generates $6.94 in profit for every $100 in assets, demonstrating efficient asset deployment.
Following the Money - Real Cash Generation
Operating Cash Flow
Merck & Co., Inc. generates strong operating cash flow of $17.87B, reflecting robust business health.
Free Cash Flow
Merck & Co., Inc. generates strong free cash flow of $14.10B, providing ample flexibility for dividends, buybacks, or growth.
FCF Per Share
Each share generates $5.71 in free cash annually.
FCF Yield
MRK converts 5.12% of its market value into free cash.
Financial Ratios Analysis
Valuation Ratios
P/E Ratio
Price to earnings ratio
30.81
vs 25 benchmark
PEG Ratio
Price/earnings to growth ratio
-0.64
vs 25 benchmark
P/B Ratio
Price to book value ratio
6.00
vs 25 benchmark
P/S Ratio
Price to sales ratio
4.19
vs 25 benchmark
Financial Health
Debt/Equity
Total debt to shareholders' equity
1.07
vs 25 benchmark
Current Ratio
Current assets to current liabilities
1.30
vs 25 benchmark
Efficiency Ratios
ROE
Return on equity percentage
0.18
vs 25 benchmark
ROA
Return on assets percentage
0.07
vs 25 benchmark
ROCE
Return on capital employed
0.18
vs 25 benchmark
How MRK Stacks Against Its Sector Peers
| Metric | MRK Value | Sector Average | Performance |
|---|---|---|---|
| P/E Ratio | 30.81 | 28.62 | Neutral |
| ROE | 17.93% | 783.00% | Weak |
| Net Margin | 13.62% | -48181.00% (disorted) | Strong |
| Debt/Equity | 1.07 | 0.39 | Weak (High Leverage) |
| Current Ratio | 1.30 | 4.12 | Neutral |
| ROA | 6.94% | -21914.00% (disorted) | Weak |
MRK outperforms its industry in 1 out of 6 key metrics, particularly excelling in Net Margin, but lagging in ROE.
Historical Growth Performance
5-Year Growth Trajectory
This section reviews Merck & Co., Inc.'s 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.
Revenue CAGR
58.00%
Industry Style: Defensive, Growth, Innovation
High GrowthEPS CAGR
160.63%
Industry Style: Defensive, Growth, Innovation
High GrowthFCF CAGR
62.10%
Industry Style: Defensive, Growth, Innovation
High Growth